XML 56 R45.htm IDEA: XBRL DOCUMENT v3.25.3
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 11 Months Ended 12 Months Ended
Jun. 18, 2024
USD ($)
May 23, 2024
USD ($)
$ / shares
shares
May 14, 2024
USD ($)
$ / shares
shares
May 08, 2024
USD ($)
$ / shares
shares
Apr. 16, 2024
USD ($)
$ / shares
shares
Mar. 25, 2024
USD ($)
$ / shares
shares
Jun. 10, 2022
USD ($)
Aug. 05, 2019
USD ($)
shares
Jun. 30, 2019
USD ($)
shares
Dec. 24, 2018
USD ($)
$ / shares
shares
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 25, 2017
USD ($)
Aug. 15, 2017
USD ($)
Aug. 31, 2016
USD ($)
Aug. 31, 2016
TWD ($)
Sep. 30, 2025
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
$ / shares
shares
Sep. 30, 2025
TWD ($)
shares
Sep. 30, 2024
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2015
TWD ($)
Jul. 31, 2025
USD ($)
Jul. 16, 2025
$ / shares
Dec. 31, 2024
Jul. 27, 2021
USD ($)
Dec. 24, 2018
$ / shares
shares
Collaborative Agreements [Line Items]                                                        
Royalty percentage                                           12.00%            
Cash equivalent                                           $ 1,600,000            
Cash received                                               $ 83,567        
Value of new shares issued                                 $ 738,370   $ 2,777,120                  
Equity method long term investment (in Shares) | shares                   1,530,000                                   1,530,000
Service agreement eligibility amount             $ 3,000,000                                          
Milestone regulatory payment amount period             3 years                                          
Loan amount                                                     $ 249,975  
Percentage of working capital convertible loan                                     5.00% 5.00%                
Fixed conversion price equal (in Dollars per share) | $ / shares                                 $ 1   $ 1                  
Licensing fee           $ 33,500,000                                            
FEYE stock (in Dollars per share) | $ / shares           $ 6                                     $ 1.65      
Milestone regulatory payment amount $ 3,500,000         $ 3,500,000                                            
Percentage of royalties of net sales           5.00%                                            
Number of shares received (in Shares) | shares   1,250,000 1,250,000 1,250,000                             1,250,000 1,250,000                
BHK Co-Development Agreement [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Description of collaborative agreements                                     On July 27, 2016, BioLite Taiwan and BHK agreed to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:   ● Upon signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment   ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment   ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment   ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment   ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment On July 27, 2016, BioLite Taiwan and BHK agreed to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:   ● Upon signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment   ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment   ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment   ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment   ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment                
Non-refundable upfront cash payment                                           $ 1,000,000            
Data and development percentage                                           10.00%            
Total cash amount                             $ 1,000,000             $ 10,000,000            
Licensing rights                               $ 31,649,000                        
Co-Dev Agreement [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Data and development percentage                                     50.00% 50.00%                
Cash amount                           $ 3,000,000                            
Addition cash payment                                     $ 3,000,000                  
Additional paid-in capital                       $ 3,000,000                                
Cash received                       450,000                                
Collaborative Agreement [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Data and development percentage                                     50.00% 50.00%                
Total cash amount                     $ 3,000,000                                  
Licensing rights                         $ 3,000,000                              
Cash amount                                     $ 3,000,000                  
Research and development expense                       $ 3,000,000                                
BioFirst Corporation Purchase Agreement [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Shares issued (in Shares) | shares               41,470 42,857                                      
Common stock consideration               $ 2,902,911 $ 3,000,000                                      
ForSeeCon Eye Corporation [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Licensing agreement $ 100,000                                                      
Licensing Agreement [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Recognized revenue                                 $ 200,000 $ 180,000 200,000   $ 296,000              
BioLite Taiwan [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Total cash (in New Dollars)                                       $ 50,000,000     $ 50,000,000          
Cash equivalent                                 $ 1,600,000   $ 1,600,000                  
Net sales profit, percentage                                     50.00% 50.00%                
Collaborative agreement with ForSeeCon Eye Corporation [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Upfront payment           $ 30,000,000                                            
Shares paid (in Shares) | shares           5,000,000                                            
Shares received (in Shares) | shares                                 5,000,000   5,000,000                  
OncoX BioPharma, Inc., [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Royalty percentage   5.00% 5.00% 5.00% 5.00%                                              
Price per share | $ / shares   $ 5 $ 5 $ 5 $ 5                                              
Shares issued (in Shares) | shares   1,250,000 1,250,000 1,250,000 1,250,000                                              
Recognized revenue                                 $ 595,950 $ 200,000 $ 595,950   $ 200,000              
Consideration paid   $ 6,250,000 $ 6,250,000 $ 6,250,000 $ 6,250,000                                              
Additional milestone payment in cash   $ 625,000 $ 625,000 $ 625,000 $ 625,000                                              
Percentage of develop and commercialize   50.00% 50.00% 50.00%                                                
Licensing fees   $ 100,000 $ 100,000 $ 100,000                                                
Rgene Corporation [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Value of new shares issued                   $ 2,550,000                                    
Percentage of note fully converted                                 37.00%   37.00%             26.65%    
Loan amount                                 $ 1,000,000   $ 1,000,000                  
Convertible loan                                 $ 500,000   $ 500,000                  
Rgene Corporation [Member] | Co-Dev Agreement [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Percentage of note fully converted                                 6.40%   6.40%                  
Rgene Corporation [Member] | Service Agreements [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Percentage of note fully converted                                 26.65%   26.65%                  
Common Stock [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Value of new shares issued                                 $ 517   $ 3,084                  
Price per share | $ / shares                                                       $ 50
Common Stock [Member] | YuanGene Corporation [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Price per share | $ / shares                   $ 1.6                                    
Common Stock [Member] | Rgene Studies [Member]                                                        
Collaborative Agreements [Line Items]                                                        
Percentage of note fully converted                                 20.00%   20.00%